Clene Inc. (CLNN) 주식 분석

회사 개요

Clene Inc. operates as a clinical-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics, with its lead drug candidate CNM-Au8 currently undergoing various clinical trials including a completed Phase 2 study. The company is classified within the Consumer Defensive sector and the Packaged Foods industry, a classification that often reflects its regulatory environment or supply chain focus rather than its primary clinical-stage business model. Clene Inc. maintains a relatively modest scale with a market capitalization of $74.67 million, annual revenue of $200,000, and an employee count of 76. These valuation figures indicate that the company is in an early-stage development phase where the primary financial objective is research and commercialization rather than generating significant operating cash flow, resulting in a market cap that does not yet reflect the potential value of its pipeline assets.

재무 건전성

The company reports revenue of $200,000 over the trailing twelve months (TTM), yet it simultaneously recorded a net income of -$26,173,000, a disparity that reveals a highly leveraged cost structure where research and development expenses significantly outpace current sales generation. Additionally, the firm generated an EBITDA of -$21,588,000, highlighting the substantial burn rate required to advance its clinical-stage therapeutics through the regulatory approval process. Free cash flow stands at -$10,136,125, indicating that the company is consuming cash reserves to fund operations and development activities rather than distributing excess liquidity to shareholders. Profitability metrics further illustrate this challenge, with a gross margin of 78.5% suggesting high production efficiency on existing sales, contrasted sharply by an operating margin of -9733.8% and a profit margin of 0.0% due to the overwhelming drag from operating expenses. On the balance sheet, Clene Inc. holds $5.19 million in cash against $21.67 million in debt, creating a situation where total liabilities exceed liquid assets. The debt-to-equity ratio is listed as N/A, which typically occurs in capitalization structures where equity is negligible or negative due to accumulated losses. Liquidity constraints are evident with a current ratio of 0.83, meaning the company's current assets are insufficient to cover its current liabilities without relying on external financing or asset sales. Return on Equity is N/A due to the lack of positive equity, while Return on Assets stands at -63.5%, demonstrating that the asset base is currently generating negative returns relative to the capital deployed.

밸류에이션 평가

Valuation multiples for Clene Inc. reflect its lack of profitability, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -4.36, implying that the market is pricing the stock based on future earnings expectations that are not yet realized in current financial statements. The price-to-book ratio is reported as -3.91, a negative figure that indicates the company's market value is below its book value, a common characteristic of capital-intensive biotech firms that have not yet achieved commercial success. Alternative valuation metrics such as the price-to-sales ratio of 373.37 and an EV/EBITDA of -4.22 suggest that the market is assigning a premium to the company's intellectual property and clinical pipeline despite the current lack of sales revenue. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $2.28 and a 52-week high of $13.50, placing the current price dynamics within a wide range that reflects speculative interest in its clinical-stage assets. The beta value of 0.62 indicates that the stock's price volatility is historically lower than the broader market, suggesting that despite its negative earnings, the security has experienced less relative movement compared to the overall market index during the reporting period.

Growth & Income

Revenue growth year-over-year has declined by 15.4%, while earnings growth is listed as N/A due to the company's consistent net losses, indicating that the business is not yet in a phase of scaling profitable operations. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, if any, are retained for reinvestment into research and development rather than being distributed to investors. This reinvestment strategy is typical for clinical-stage pharmaceutical companies that prioritize advancing their lead drug candidates through clinical trials over providing immediate income to shareholders. Consequently, the overall growth and income profile for Clene Inc. is characterized by a focus on capital appreciation driven by clinical trial results rather than current income generation or dividend sustainability.